Skip to content

Closing the Rare Disease Innovation Gap

Share this page

The Food and Drug Administration recently approved a novel therapy for Duchenne muscular dystrophy utilizing this special pathway when the science is imperfect but the disease is deadly. We support the approval but also note that the development program left many questions unresolved

Related Articles